|
WINNIPEG, Manitoba – July 13, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce today that the United States Patent and Trademark Office has issued US Patent 7,754,495 entitled “Methods for Early Diagnosing of an Increased Risk of Preeclampsia”. The issued patent is a valuable addition to Miraculins’ portfolio of issued and pending patents protecting markers in its preeclampsia program, including Endoglin, the lead marker in the program. Miraculins’ preeclampsia program is being advanced in partnership with the Biosite division of Inverness Medical Innovations (NYSE:IMA).
Read More
|
|
Company’s assay the first designed for the detection of sEng in urine
WINNIPEG, Manitoba – May 17, 2010 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to update the market on its preeclampsia program by announcing the development of an ultrasensitive assay for the detection of soluble endoglin (sEng). The test has been optimized for serum and urine in the widely utilized ELISA format. As a further benefit, Miraculins’ sEng test requires significantly less sample volume than competing tests. sEng is the lead marker from the Company’s preeclampsia biomarker portfolio.
Read More
|
|
WINNIPEG, Manitoba – May 10, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent (LOI) with PreMD Inc. to license the exclusive worldwide rights to the PreVu Skin Cholesterol Test, a simple non-invasive diagnostic test for the quantification of skin tissue cholesterol (skin sterol). Developed as a cost effective method of assisting with the risk assessment of coronary artery disease (CAD), the product has received FDA clearance and has been successfully test marketed in the United States and Canada.
Read More
|
|
WINNIPEG, Manitoba – April 1, 2010 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, has closed its previously announced private placement offering (the "Offering") with aggregate gross proceeds to the Company of $510,000 from the sale of 10,200,000 units ("Units") at a price of $0.05 per Unit.
Read More
|
|
Agreement Includes Fee From Inverness to Acquire Exclusive Option to License Worldwide Rights
WINNIPEG, Manitoba – January 7, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has entered into a partnership with Inverness Medical Innovations, Inc. (NYSE:IMA), a global leader in the convergence of medical diagnostic testing and health management, to advance and commercialize Miraculins’ preeclampsia technology.
Read More
|
|
|